NCT07010692

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Using Fractional Lasers and Tirbanibulin Ointment to Treat Keratinocyte Carcinomas

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Bruce Robinson, MD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.

Conditions

• Keratinocyte Carcinoma
• Basal Cell Carcinomas
• Squamous Cell Carcinoma
• Skin Cancer

Interventions

Type	Name	Description
DRUG	Tirbanibulin ointment 1%	Tirbanibulin ointment is applied for 5 nights following the in-office fractional laser procedure for patients with more advanced carcinomas.
DEVICE	non-ablative fractional laser	Every skin cancer will be treated with two wavelengths (1550nm and 1927nm) of a non-ablative fractional laser.

Timeline

• Start date: 2025-05-16
• Primary completion: 2030-05-01
• Completion: 2030-06-01
• First posted: 2025-06-08
• Last updated: 2025-09-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study
• FDA-regulated device study